HitGen: Partner BioAge launches Phase I clinical study of novel NLRP3 inhibitor BGE-102

Zhitong
2025.09.15 01:12

According to news from HitGen, the company's partner BioAgeLabs, Inc. has recently launched a Phase I clinical study of the novel and potent NLRP3 inhibitor BGE-102. The lead compound of BGE-102 was obtained through screening of HitGen's DNA-encoded compound library. According to the cooperation agreement between the two parties, HitGen will receive relevant milestone payments, the specific amount of which has not been disclosed. BGE-102 is an orally administered small molecule NLRP3 inhibitor with a novel structure, high activity, and good brain penetration, developed for the treatment of obesity

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.